Agios Pharmaceuticals (BMV:AGIO *) - Aandelenkoers, Nieuws & Analyse

AGIO * Overzicht aandelen

Agios Pharmaceuticals, Inc., een biofarmaceutisch bedrijf, ontdekt en ontwikkelt medicijnen op het gebied van celmetabolisme in de Verenigde Staten. Meer informatie

AGIO * fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	3/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 71.1% onder onze schatting van de reële waarde

De omzet zal naar verwachting met 55.42% per jaar groeien

Dit jaar winstgevend geworden

Risicoanalyse

Hoog niveau van niet-contante inkomsten

De winst zal naar verwachting de komende drie jaar met gemiddeld 56.7% per jaar dalen.

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

+ 1 meer risico

Agios Pharmaceuticals, Inc. Concurrenten

PharmaEssentia

TWSE:6446

NT$189.7b

PeptiDream

TSE:4587

JP¥332.3b

Protagonist Therapeutics

NasdaqGM:PTGX

US$2.4b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Agios Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$983.02
52 Week Hoogtepunt	US$983.02
52 Week Laag	US$397.93
Bèta	0.75
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	18.44%
5 jaar verandering	68.61%
Verandering sinds IPO	4.02%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	AGIO *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe AGIO * presteerde ten opzichte van de MX Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe AGIO * presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is AGIO *'s price volatile compared to industry and market?
AGIO * volatility
AGIO * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: De aandelenkoers van AGIO * is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van AGIO * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	385	Brian Goff	www.agios.com

Agios Pharmaceuticals, Inc, een biofarmaceutisch bedrijf, ontdekt en ontwikkelt geneesmiddelen op het gebied van celmetabolisme in de Verenigde Staten. Het belangrijkste product is PYRUKYND (mitapivat), een activator van wild-type en mutante pyruvaat kinase (PK) enzymen voor de behandeling van hemolytische anemieën. Het bedrijf ontwikkelt AG-946, een PK activator voor de behandeling van myelodysplastisch syndroom met een lager risico en hemolytische anemieën; en AG-181, een fenylalanine hydroxylase stabilisator voor de behandeling van fenylketonurie.

Agios Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Agios Pharmaceuticals zich tot de beurswaarde?
AGIO * fundamentele statistieken
Marktkapitalisatie	Mex$63.24b
Inkomsten(TTM)	Mex$13.69b
Inkomsten(TTM)	Mex$667.34m

4.6x

Koers/Winstverhouding

94.8x

P/S-verhouding

Is AGIO * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AGIO * resultatenrekening (TTM)
Inkomsten	US$32.87m
Kosten van inkomsten	US$299.46m
Brutowinst	-US$266.58m
Overige uitgaven	-US$940.89m
Inkomsten	US$674.31m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	11.82
Brutomarge	-811.00%
Nettowinstmarge	2,051.38%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde AGIO * op de lange termijn?

Bekijk historische prestaties en vergelijking

AGIO * Overzicht aandelen

Beloningen

Risicoanalyse

Agios Pharmaceuticals, Inc. Concurrenten

TWSE:6446

NT$189.7b

TSE:4587

JP¥332.3b

NasdaqGM:PTGX

US$2.4b

NasdaqCM:CPRX

US$2.5b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Recent updates

Agios Pharmaceuticals, Inc. Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

Agios to Receive $1.1 Billion in Milestone Payments Following FDA Approval of Vorasidenib

Agios Pharmaceuticals, Inc. Announces Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat in Children with PK Deficiency Who Are Regularly Transfused

Agios Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

Agios Pharmaceuticals, Inc. Announces Phase 3 Energize-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia